Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Shanghai Qisheng Biological Preparation develops and manufactures biomedical materials and medical devices including commercialized chitosan-based gels, sodium hyaluronate gels, collagen sponges, lubricant eye drops, and cross-linked hyaluronic acid injectables. Their products are widely used across ophthalmology, orthopedics, general surgery, obstetrics & gynecology as well as plastic/cosmetic surgery. They have conducted at least one Phase IV clinical trial comparing their chitosan product to sodium hyaluronate injection for knee osteoarthritis. The company has a strong record of regulatory approvals including multiple CFDA Class III certificates—the highest class for Chinese medical devices—and continues to develop new hydrogel technologies such as thermal-sensitive chitosan gels targeting expanded indications like brain/spinal membrane repair and sustained-release drug delivery.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Shanghai Qisheng Biological Preparation.